HIV&AIDS: Symposium - Theme B - s100 prescriber session - Changing landscapes in Therapy
Tracks
1
| Wednesday, November 8, 2017 |
| 11:30 AM - 1:00 PM |
| Royal Theatre |
Details
This session will focus on issues pertinent to current prescribers including drug-drug interactions with new antiretrovirals, update on 2 drug regimens and strategies to minimise drug toxicity. Learning Objectives: Participants will gain knowledge on drug-drug interactions with newer agents such as cobicistat and tenofovir alefenamide, be updated on the current status of 2 drug antiretroviral regimens, identify situations where it is better to stop an antiretroviral causing a toxicity or continue the antiretroviral but treat the toxicity with an other method or drug, and be updated on polypharmacy for people with HIV from a large Australian cohort.
Speaker
Ms Alison Duncan
Clinical Pharmacist
The Alfred Hospital
Drug Drug interactions – When is cobicistat not ritonavir, when is TAF not TDF
11:30 AM - 11:52 AMBiography
Alison is a senior clinical pharmacist at Alfred Health, and team leader for HIV pharmacy services at the Alfred and Melbourne Sexual Health Centre. Alison and her team are involved in both inpatient and outpatient services to HIV positive patients, and enjoy working with medical/nursing colleagues to improve services
Professor Mark Boyd
Chair Of Medicine
University of Adelaide
Dr Krista Siefried
Clinical Research Lead
The National Centre For Clinical Research On Emerging Drugs
Dr Krista Siefried
Clinical Research Lead
The National Centre For Clinical Research On Emerging Drugs
Prof Andrew Carr
Director - HIV and Immunology Unit
St Vincent's Hospital, Sydney
HIV Comorbidities: Treat, Switch ART, or Both?
12:14 PM - 12:36 PMBiography
Professor Andrew Carr is a clinical immunologist and immunopathologist, and Heads the HIV, Immunology and Infectious Diseases Unit and the Clinical Research Program, Centre for Applied Medical Research, St Vincent’s Hospital, Sydney. He has authored over 300 peer-reviewed publications, mostly on antiretroviral complications and comorbidities.
